Analysts expect over 2023 revenue increase UCB

Tomorrow UCB will publish its past quarters results. Over the current book year the company from could achieve a revenue around 5.17 billion euros (consensus estimates). This is slightly lower than 2022's revenue of 5.52 billion euros.

Historical revenues and results UCB plus estimates 2023

The analysts expect for 2023 a net profit of 686 million euros. The majority of the analysts expects for this year a profit per share of 3.75 euros. With this the price/earnings-ratio is 25.77.

Per share the analysts anticipate on a dividend of 1.35 euros per share. Thus the dividend yield equals 1.4 percent. The average dividend yield of the pharmaceutical companies is an attractive 2.07 percent.

Most recent target prices around 106 euros

The most recent recommendations for the pharmaceutical company are from Citigroup , KBC Securities and HSBC .

UCB 's market capitalization is around 18.28 billion euros.

At 9.28 the stock trades 0.04 percent higher at 96.64 euros.

Historical stock prices UCB2007-2023

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.